| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FASTK |
| Uniprot No | Q14296 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-549aa |
| 氨基酸序列 | MRRPRGEPGP RAPRPTEGAT CAGPGESWSP SPNSMLRVLL SAQTSPARLS GLLLIPPVQP CCLGPSKWGD RPVGGGPSAG PVQGLQRLLE QAKSPGELLR WLGQNPSKVR AHHYSVALRR LGQLLGSRPR PPPVEQVTLQ DLSQLIIRNC PSFDIHTIHV CLHLAVLLGF PSDGPLVCAL EQERRLRLPP KPPPPLQPLL RGGQGLEAAL SCPRFLRYPR QHLISSLAEA RPEELTPHVM VLLAQHLARH RLREPQLLEA IAHFLVVQET QLSSKVVQKL VLPFGRLNYL PLEQQFMPCL ERILAREAGV APLATVNILM SLCQLRCLPF RALHFVFSPG FINYISGTPH ALIVRRYLSL LDTAVELELP GYRGPRLPRR QQVPIFPQPL ITDRARCKYS HKDIVAEGLR QLLGEEKYRQ DLTVPPGYCT DFLLCASSSG AVLPVRTQDP FLPYPPRSCP QGQAASSATT RDPAQRVVLV LRERWHFCRD GRVLLGSRAL RERHLGLMGY QLLPLPFEEL ESQRGLPQLK SYLRQKLQAL GLRWGPEGG |
| 预测分子量 | 84 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FASTK重组蛋白的3篇代表性文献概览：
1. **《Fas-Activated Serine/Threonine Kinase (FASTK) Modulates Mitochondrial RNA Stability and Protein Synthesis》**
*作者：Antonicka H. et al. (2016), Cell Reports*
摘要：研究揭示了FASTK通过结合线粒体RNA调控其稳定性，并参与呼吸链复合物的翻译过程，重组FASTK蛋白实验证实其在维持线粒体功能中的关键作用。
2. **《Cloning and Characterization of FASTK, a Novel Protein Involved in Apoptosis》**
*作者：Simarro M. et al. (2004), Journal of Biological Chemistry*
摘要：首次报道FASTK基因的克隆与重组蛋白表达，证实其作为Fas信号通路中的丝氨酸/苏氨酸激酶，参与调控细胞凋亡，并通过体外激酶实验验证功能。
3. **《Structural Insights into FASTK Family Proteins in Mitochondrial RNA Processing》**
*作者：Jourdain A.A. et al. (2017), Nature Communications*
摘要：通过重组FASTK蛋白的晶体结构解析，阐明其RNA结合结构域特征，揭示其在调控线粒体RNA剪接和成熟中的分子机制。
4. **《FASTK Cooperates with IGF2BP1 to Promote Cell Migration in Colorectal Cancer》**
*作者：Zhang Y. et al. (2020), Oncogene*
摘要：利用重组FASTK蛋白进行功能实验，发现其通过与RNA结合蛋白IGF2BP1互作，增强结直肠癌细胞迁移能力，提示其作为癌症治疗靶点的潜力。
注：以上文献为领域内代表性研究，具体细节建议通过PubMed或期刊官网检索原文。
FASTK (Fas-Activated Serine/Threonine Kinase) is a serine/threonine kinase initially identified for its role in Fas-mediated apoptosis. Discovered in the late 1990s, FASTK is activated upon Fas receptor engagement, a critical pathway in programmed cell death. Unlike canonical kinases, FASTK exhibits unique localization and regulatory mechanisms, primarily residing in mitochondria and nucleoli, suggesting multifaceted roles beyond apoptosis. Structurally, it contains an N-terminal mitochondrial targeting sequence, RNA-binding domains, and a C-terminal kinase domain, enabling interactions with RNA and proteins.
FASTK is implicated in mitochondrial RNA processing, particularly in the maturation of transcripts essential for oxidative phosphorylation. Studies reveal its involvement in stabilizing and processing mitochondrial 16S rRNA, linking it to cellular energy metabolism. Additionally, FASTK regulates stress-induced responses, including inflammation and autophagy, through interactions with signaling molecules like TRAF2 and ATG5. Its dual localization allows cross-talk between mitochondrial function and nuclear stress pathways.
Dysregulation of FASTK is associated with diseases such as neurodegeneration, cancer, and cardiovascular disorders. For example, reduced FASTK expression correlates with mitochondrial dysfunction in Alzheimer’s disease, while its overexpression in glioblastoma promotes tumor survival. These findings highlight FASTK as a potential therapeutic target.
Recombinant FASTK proteins, produced via bacterial or mammalian expression systems, are vital tools for studying its kinase activity, RNA-binding properties, and interactions. They enable in vitro assays, structural studies, and inhibitor screening. Research using recombinant FASTK continues to unravel its complex roles in cellular homeostasis and disease, offering insights into novel treatment strategies targeting mitochondrial metabolism or apoptosis pathways.
×
